Skip to NavigationSkip to content

Dr Lisa Rojkjaer, head of clinical development, MorphoSys

Published on: 15/10/09

MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development.

Dr Rojkjaer joins MorphoSys from Novartis where she most recently held the position of head of medical affairs - hematology, Europe.

Before that she was global clinical programme head for Exjade, where she was responsible for all clinical activities in Europe for Novartis' haematology portfolio including Gleevec and Exjade.

Prior to Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the director of global medical affairs biopharmaceuticals and later director, clinical development haematology.

During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US haematology portfolio amongst other accomplishments.

Dr Rojkjaer is a board certified haematologist and received her medical degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in haematology.

She has held academic and hospital appointments in the US, Canada and Europe.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches